Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features.

作者: Francesco Puleo , Rémy Nicolle , Yuna Blum , Jérôme Cros , Laetitia Marisa

DOI: 10.1053/J.GASTRO.2018.08.033

关键词:

摘要: Background & Aims Genomic studies have revealed subtypes of pancreatic ductal adenocarcinoma (PDA) based on their molecular features, but different reported classification systems. It is a challenge to obtain high-quality, freshly frozen tissue for clinical analysis and determination PDA subtypes. We aimed redefine using large number formalin-fixed paraffin-embedded samples, which are more amenable routine evaluation. Methods collected samples from 309 consecutive patients who underwent surgery September 1996 through December 2010 at 4 academic hospitals in Europe; nontumor were not included. Samples formalin fixed paraffin embedded. DNA RNA isolated; gene expression, targeted sequencing, immunohistochemical analyses performed. used independent component deconvolute normal, tumor, microenvironment transcriptome patterns samples. devised systems an unsupervised consensus clustering approach our data set after removing normal contamination components. associated with overall survival disease-free Cox proportional hazards regression estimation hazard ratios 95% confidence interval. The Cancer Genome Consortium International sets as validation cohorts. Results validated the previously basal-like classical tumor-specific PDAs. identified features PDA, including expression patterns, that allowed tumors be categorized into 5 subtypes, called pure basal like, stroma activated, desmoplastic, classical, immune classical. These cancer cells could by pharmacologic agents. Tumor patient outcomes, sets. also observed exocrine signal acinar cell (from tissue). Conclusions system tumor microenvironment. This might select therapies predict outcomes. found evidence exocrine-like (called ADEX) subtype resulted cells. ArrayExpress accession number: E-MTAB-6134.

参考文章(34)
Mark S Talamonti, Christine A Iacobuzio-Donahue, Michael A Hollingsworth, Jen Jen Yeh, Richard A Moffitt, Raoud Marayati, Elizabeth L Flate, Keith E Volmar, S Gabriela Herrera Loeza, Katherine A Hoadley, Naim U Rashid, Lindsay A Williams, Samuel C Eaton, Alexander H Chung, Jadwiga K Smyla, Judy M Anderson, Hong Jin Kim, David J Bentrem, Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma Nature Genetics. ,vol. 47, pp. 1168- 1178 ,(2015) , 10.1038/NG.3398
Justin Guinney, Rodrigo Dienstmann, Xin Wang, Aurélien De Reynies, Andreas Schlicker, Charlotte Soneson, Laetitia Marisa, Paul Roepman, Gift Nyamundanda, Paolo Angelino, Brian M Bot, Jeffrey S Morris, Iris M Simon, Sarah Gerster, Evelyn Fessler, Felipe De Sousa E Melo, Edoardo Missiaglia, Hena Ramay, David Barras, Krisztian Homicsko, Dipen Maru, Ganiraju C Manyam, Bradley Broom, Valerie Boige, Beatriz Perez-Villamil, Ted Laderas, Ramon Salazar, Joe W Gray, Douglas Hanahan, Josep Tabernero, Rene Bernards, Stephen H Friend, Pierre Laurent-Puig, Jan Paul Medema, Anguraj Sadanandam, Lodewyk Wessels, Mauro Delorenzi, Scott Kopetz, Louis Vermeulen, Sabine Tejpar, None, The consensus molecular subtypes of colorectal cancer Nature Medicine. ,vol. 21, pp. 1350- 1356 ,(2015) , 10.1038/NM.3967
Albrecht Neesse, Hana Algül, David A Tuveson, Thomas M Gress, Stromal biology and therapy in pancreatic cancer: a changing paradigm Gut. ,vol. 64, pp. 1476- 1484 ,(2015) , 10.1136/GUTJNL-2015-309304
James J. Farrell, Hany Elsaleh, Miguel Garcia, Raymond Lai, Ali Ammar, William F. Regine, Ross Abrams, A. Bowen Benson, John Macdonald, Carol E. Cass, Adam P. Dicker, John R. Mackey, Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer Gastroenterology. ,vol. 136, pp. 187- 195 ,(2009) , 10.1053/J.GASTRO.2008.09.067
Lola Rahib, Benjamin D. Smith, Rhonda Aizenberg, Allison B. Rosenzweig, Julie M. Fleshman, Lynn M. Matrisian, Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States Cancer Research. ,vol. 74, pp. 2913- 2921 ,(2014) , 10.1158/0008-5472.CAN-14-0155
J. J. Lee, R. M. Perera, H. Wang, D.-C. Wu, X. S. Liu, S. Han, J. Fitamant, P. D. Jones, K. S. Ghanta, S. Kawano, J. M. Nagle, V. Deshpande, Y. Boucher, T. Kato, J. K. Chen, J. K. Willmann, N. Bardeesy, P. A. Beachy, Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 111, ,(2014) , 10.1073/PNAS.1411679111
Andrew D. Rhim, Paul E. Oberstein, Dafydd H. Thomas, Emily T. Mirek, Carmine F. Palermo, Stephen A. Sastra, Erin N. Dekleva, Tyler Saunders, Claudia P. Becerra, Ian W. Tattersall, C. Benedikt Westphalen, Jan Kitajewski, Maite G. Fernandez-Barrena, Martin E. Fernandez-Zapico, Christine Iacobuzio-Donahue, Kenneth P. Olive, Ben Z. Stanger, Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma Cancer Cell. ,vol. 25, pp. 735- 747 ,(2014) , 10.1016/J.CCR.2014.04.021
Raphaël Maréchal, Jean–Baptiste Bachet, John R Mackey, Cécile Dalban, Pieter Demetter, Kathryn Graham, Anne Couvelard, Magali Svrcek, Armelle Bardier–Dupas, Pascal Hammel, Alain Sauvanet, Christophe Louvet, François Paye, Philippe Rougier, Christophe Penna, Thierry André, Charles Dumontet, Carol E Cass, Lars Petter Jordheim, Eva–Laure Matera, Jean Closset, Isabelle Salmon, Jacques Devière, Jean–François Emile, Jean–Luc Van Laethem, None, Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma Gastroenterology. ,vol. 143, pp. 664- 674.e6 ,(2012) , 10.1053/J.GASTRO.2012.06.006
Jean-Baptiste Bachet, Raphael Maréchal, Pieter Demetter, Franck Bonnetain, Jérôme Cros, Magali Svrcek, Armelle Bardier-Dupas, Pascal Hammel, Alain Sauvanet, Christophe Louvet, François Paye, Jean-Christophe Vaillant, Thierry André, Jean Closset, Isabelle Salmon, Jean-François Emile, Jean-Luc Van Laethem, S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. European Journal of Cancer. ,vol. 49, pp. 2643- 2653 ,(2013) , 10.1016/J.EJCA.2013.04.017
G. Feldmann, V. Fendrich, K. McGovern, D. Bedja, S. Bisht, H. Alvarez, J.-B. M. Koorstra, N. Habbe, C. Karikari, M. Mullendore, K. L. Gabrielson, R. Sharma, W. Matsui, A. Maitra, An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer Molecular Cancer Therapeutics. ,vol. 7, pp. 2725- 2735 ,(2008) , 10.1158/1535-7163.MCT-08-0573